nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?
|
Le Chevalier, T. |
|
|
21 |
S7 |
p. vii196-vii198 |
artikel |
2 |
Advances in neuroendocrine lung tumors
|
Travis, W.D. |
|
|
21 |
S7 |
p. vii65-vii71 |
artikel |
3 |
Advances in systemic treatment of melanoma
|
Eggermont, A.M.M. |
|
|
21 |
S7 |
p. vii339-vii344 |
artikel |
4 |
Advances in the treatment of metastatic or unresectable biliary tract cancer
|
Valle, J.W. |
|
|
21 |
S7 |
p. vii345-vii348 |
artikel |
5 |
Anemia in cancer
|
Dicato, M. |
|
|
21 |
S7 |
p. vii167-vii172 |
artikel |
6 |
Benefits and adverse effects of endocrine therapy
|
Colleoni, M. |
|
|
21 |
S7 |
p. vii107-vii111 |
artikel |
7 |
Cancer of unknown primary site: 20 questions to be answered
|
Pavlidis, N. |
|
|
21 |
S7 |
p. vii303-vii307 |
artikel |
8 |
Cancer stem cells
|
Cordon-Cardo, C. |
|
|
21 |
S7 |
p. vii93-vii94 |
artikel |
9 |
Cardiotoxicity
|
Brana, I. |
|
|
21 |
S7 |
p. vii173-vii179 |
artikel |
10 |
Chemotherapy: which drug and when?
|
Sobrero, A. |
|
|
21 |
S7 |
p. vii130-vii133 |
artikel |
11 |
Chemotherapy with or without trastuzumab
|
Oakman, C. |
|
|
21 |
S7 |
p. vii112-vii119 |
artikel |
12 |
Chronic lymphocytic leukemia
|
Hallek, Michael |
|
|
21 |
S7 |
p. vii154-vii164 |
artikel |
13 |
Circulating cancer cells
|
Mavroudis, D. |
|
|
21 |
S7 |
p. vii95-vii100 |
artikel |
14 |
Consequences of targeted treatments for second-line therapy
|
De Maio, E. |
|
|
21 |
S7 |
p. vii234-vii240 |
artikel |
15 |
Do we have markers to select patients for adjuvant therapies of non-small-cell lung cancer?
|
Konopa, K. |
|
|
21 |
S7 |
p. vii199-vii202 |
artikel |
16 |
Early stage non-small-cell lung cancer: challenges in staging and adjuvant treatment: evidence-based staging
|
Vansteenkiste, J. |
|
|
21 |
S7 |
p. vii189-vii195 |
artikel |
17 |
Editorial Board
|
|
|
|
21 |
S7 |
p. ii-iii |
artikel |
18 |
ESMO Education
|
|
|
|
21 |
S7 |
p. vii5-vii7 |
artikel |
19 |
ESMO Educational and Scientific activities
|
|
|
|
21 |
S7 |
p. vii10-vii11 |
artikel |
20 |
ESMO Fellowship Program
|
|
|
|
21 |
S7 |
p. vii12-vii16 |
artikel |
21 |
ESMO-MORA
|
|
|
|
21 |
S7 |
p. vii8-vii9 |
artikel |
22 |
European Society for Medical Oncology Committees
|
|
|
|
21 |
S7 |
p. vii18-vii19 |
artikel |
23 |
Follicular lymphoma
|
Ghielmini, M. |
|
|
21 |
S7 |
p. vii151-vii153 |
artikel |
24 |
Gastrointestinal neuroendocrine tumors
|
Öberg, K.E. |
|
|
21 |
S7 |
p. vii72-vii80 |
artikel |
25 |
Genetic counselling for hereditary predisposition to ovarian and breast cancer
|
Mackay, J. |
|
|
21 |
S7 |
p. vii334-vii338 |
artikel |
26 |
Histology-driven chemotherapy of soft-tissue sarcoma
|
Eriksson, M. |
|
|
21 |
S7 |
p. vii270-vii276 |
artikel |
27 |
Horizon scanning for novel therapeutics for the treatment of prostate cancer
|
Bianchini, D. |
|
|
21 |
S7 |
p. vii43-vii55 |
artikel |
28 |
How to integrate current knowledge in selecting patients for first line in NSCLC?
|
Felip, E. |
|
|
21 |
S7 |
p. vii230-vii233 |
artikel |
29 |
How to integrate molecular targeted agents in the continuum of care
|
Köhne, C.-H. |
|
|
21 |
S7 |
p. vii134-vii139 |
artikel |
30 |
How to select targeted therapy in renal cell cancer
|
Escudier, B. |
|
|
21 |
S7 |
p. vii59-vii62 |
artikel |
31 |
Integrating systemic agents into multimodality treatment of locally advanced head and neck cancer
|
Posner, M.R. |
|
|
21 |
S7 |
p. vii246-vii251 |
artikel |
32 |
Introduction from the ESMO 2010 Educational Committee Chair
|
|
|
|
21 |
S7 |
p. vii24 |
artikel |
33 |
Is there any role for surgery in the multidisciplinary treatment of esophageal cancer?
|
Stahl, M. |
|
|
21 |
S7 |
p. vii283-vii285 |
artikel |
34 |
Merkel cell carcinoma
|
Becker, J.C. |
|
|
21 |
S7 |
p. vii81-vii85 |
artikel |
35 |
Mesothelioma
|
Weder, W. |
|
|
21 |
S7 |
p. vii326-vii333 |
artikel |
36 |
Multimodality treatment for localized gastro-oesophageal cancer
|
Okines, A.F.C. |
|
|
21 |
S7 |
p. vii286-vii293 |
artikel |
37 |
Multiple myeloma
|
Dimopoulos, M.A. |
|
|
21 |
S7 |
p. vii143-vii150 |
artikel |
38 |
Multiple myeloma
|
Bladé, J. |
|
|
21 |
S7 |
p. vii313-vii319 |
artikel |
39 |
Nasopharyngeal carcinoma
|
Chan, A.T.C. |
|
|
21 |
S7 |
p. vii308-vii312 |
artikel |
40 |
New agents for bladder cancer
|
Bellmunt, J. |
|
|
21 |
S7 |
p. vii56-vii58 |
artikel |
41 |
New trends for staging and therapy for localized gastroesophageal cancer: the role of PET
|
Lordick, F. |
|
|
21 |
S7 |
p. vii294-vii299 |
artikel |
42 |
Optimal treatment for recurrent/metastatic head and neck cancer
|
Vermorken, J.B. |
|
|
21 |
S7 |
p. vii252-vii261 |
artikel |
43 |
Optimal treatment for relapsing ovarian cancer
|
Ledermann, J.A. |
|
|
21 |
S7 |
p. vii218-vii222 |
artikel |
44 |
Osteosarcoma
|
Ritter, J. |
|
|
21 |
S7 |
p. vii320-vii325 |
artikel |
45 |
Prevention and treatment of side-effects of systemic treatment: bone loss
|
Body, J.-J. |
|
|
21 |
S7 |
p. vii180-vii185 |
artikel |
46 |
Proteomics as a guiding tool for more effective personalized therapy
|
Lee, J.-M. |
|
|
21 |
S7 |
p. vii205-vii210 |
artikel |
47 |
Should we continue to use the term non-small-cell lung cancer?
|
Gazdar, A.F. |
|
|
21 |
S7 |
p. vii225-vii229 |
artikel |
48 |
Soft tissue sarcoma: from molecular diagnosis to selection of treatment. Pathological diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies
|
Wardelmann, E. |
|
|
21 |
S7 |
p. vii265-vii269 |
artikel |
49 |
Table of Contents
|
|
|
|
21 |
S7 |
p. v-vi |
artikel |
50 |
Targeted therapies in soft tissue sarcomas
|
Judson, I. |
|
|
21 |
S7 |
p. vii277-vii280 |
artikel |
51 |
The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer
|
Bookman, M.A. |
|
|
21 |
S7 |
p. vii211-vii217 |
artikel |
52 |
The epithelial–mesenchymal transition (EMT) phenomenon
|
Savagner, P. |
|
|
21 |
S7 |
p. vii89-vii92 |
artikel |
53 |
The role of human papillomavirus infection in head and neck cancers
|
Syrjänen, S. |
|
|
21 |
S7 |
p. vii243-vii245 |
artikel |
54 |
35th ESMO Congress Officers
|
|
|
|
21 |
S7 |
p. vii20-vii21 |
artikel |
55 |
35th ESMO Congress Organization
|
|
|
|
21 |
S7 |
p. vii22-vii23 |
artikel |
56 |
Title Page
|
|
|
|
21 |
S7 |
p. iv |
artikel |
57 |
Treatment of HER2-overexpressing breast cancer
|
Baselga, J. |
|
|
21 |
S7 |
p. vii36-vii40 |
artikel |
58 |
Treatment of pT1N0 breast cancer: multigene predictors to assess risk of relapse
|
Fumagalli, D. |
|
|
21 |
S7 |
p. vii103-vii106 |
artikel |
59 |
Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?
|
Berrada, N. |
|
|
21 |
S7 |
p. vii30-vii35 |
artikel |
60 |
What can the molecular pathologist offer for optimal decision making?
|
Richman, S.D. |
|
|
21 |
S7 |
p. vii123-vii129 |
artikel |
61 |
What can the pathologist offer for optimal treatment choice?
|
Viale, G. |
|
|
21 |
S7 |
p. vii27-vii29 |
artikel |
62 |
Young Oncologists
|
|
|
|
21 |
S7 |
p. vii17 |
artikel |